US FDA Opens Door For J&J's Spravato To Another MDD Population
Executive Summary
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
You may also be interested in...
Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial
The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.
COMPASS Psilocybin Depression Data Excite Despite Safety Issues
The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.
Psychedelics For CNS Disorders: Understanding The Opportunity
Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.